Security key
62856X300
Q/C TECHNOLOGIES, INC. - Common Stock, par value $0.001 per share (QCLS)
CUSIP: 62856X300
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 16,820
- Total 13F value
- $69,803
- Share change
- +16,820
- SEC-reported price per share
- $4.15
- Number of holders
- 11
- Value change
- +$69,803
- Number of buys
- 11
- Shares outstanding
- 11,453,200
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
11
Top holders
10
QCLS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Q/C TECHNOLOGIES, INC. SEC filings
Q/C TECHNOLOGIES, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 62856X300
Recent filing periods:
Ownership snapshot
Top reported holders of QCLS - Q/C TECHNOLOGIES, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PharmaCyte Biotech, Inc.
Disclosed value leader
Paul Rivard
Comparable rows
0/8
Latest evidence
04 Sep 2025
3/4/5
Highest disclosed value: $444,000
8 rows are not safely comparable across share classes.
Showing 1-6 of 8 holder rows.
Quick read
Paul Rivard has the largest disclosed position value at $444K.
0 of 8 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Paul Rivard's linked filing trail.
Disclosed position value
Top 1
Paul Rivard
$444K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 8 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
—
1,779,730 shares
mixed-class rows
|
— | 04 Sep 2025 |
| Paul Rivard |
3/4/5
Chief Legal Officer
|
—
class O/S missing
|
$444,000
400,000 shares
|
— | 24 Aug 2023 |
| Craig Eagle |
3/4/5
Director
|
—
class O/S missing
|
—
475,000 shares
|
— | 07 Jun 2023 |
| Christopher Chapman MD |
3/4/5
President, Chief Med. Officer, Director
|
—
class O/S missing
|
—
300,000 shares
|
— | 07 Jun 2023 |
| Adam Kaplin |
3/4/5
Chief Scientific Officer
|
—
class O/S missing
|
—
150,000 shares
|
— | 07 Jun 2023 |
| Christopher C. Schreiber |
3/4/5
Director
|
—
class O/S missing
|
—
150,000 shares
|
— | 07 Jun 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
11
Shares
16,820
Rows available
11
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q1 2026 Across Filers
Q1 2026 holders
17
Q3 2025 holders
11
Holder diff
-6
| Investor | Q1 2026 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend